The Medicines Patent Pool has signed agreements with nine patent holders for thirteen HIV antiretrovirals, one HIV technology platform, a tuberculosis treatment and three hepatitis C direct-acting antivirals. 23 generic manufacturers and product developers have now signed MPP sublicensing agreements.

Overview of all licensing and sublicensing agreements

The below table provides an overview of manufacturer filing timelines per combination, countrywide filing status and plans for registration. Generic competition is making a difference in fostering lower prices and improving treatment coverage. Generic partners have distributed 22 million patient years of HIV and hepatitis C products, saving international procurers USD1.06 million (Jan. 2012-December 2018).

A PPT presentation, highlighting the progress of MPP’s generic partners in developing MPP-licensed medicines, is also available for download and updated every quarter (last update: March 2019): PPT Update on Progress of MPP Sublicensees

Last update of the table: July 2019 (data as of March 2019)

[WHO-PQ] Prequalification from the World Health Organization | [USFDA] U.S. Food and Drug Administration | [ERP] Expert Review Panel led by the World Health Organization

This website uses cookies to ensure you get the best experience on our website. Learn More